

[Help](#)[Logout](#)[Main Menu](#)[Search Form](#)[Posting Counts](#)[Show S Numbers](#)[Edit S Numbers](#)

Search Results -

Term	Documents
UNIVERSAL.USPT.	67784
UNIVERSALS USPT	81
(6 AND UNIVERSAL).USPT.	4

Database: US Patents Full-Text Database

16 and universal

[Refine Search](#)

Search History

<u>DB Name</u>	<u>Query</u>	<u>Hit Count</u>	<u>Set Name</u>
USPT	16 and universal	4	<u>L7</u>
USPT	15 and (medium or media)	36	<u>L6</u>
USPT	14 and cyto!og\$4 and molecular	40	<u>L5</u>
USPT	13 and (rna or dna or protein)	1770	<u>L4</u>
USPT	11 and 12 and preservative	3318	<u>L3</u>
USPT	murexide or (chromotropic adj acid) or edta or phenanthroline or thiourea	50740	<u>L2</u>
USPT	formaldehyde or formalin or glutaraldehyde	82789	<u>L1</u>

[Help](#)[Logout](#)[Main Menu](#)[Search Form](#)[Posting Counts](#)[Show S Numbers](#)[Edit S Numbers](#)[Generate Collection](#)**Search Results - Record(s) 1 through 20 of 36 returned.**☐ 1. Document ID: US 6022951 A

Entry 1 of 36

File: USPT

Feb 8, 2000

US-PAT-NO: 6022951

DOCUMENT-IDENTIFIER: US 6022951 A

TITLE: Streptavidin mutants

DATE-ISSUED: February 8, 2000

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Sano; Takeshi	Boston	MA	02114	N/A
Cantor; Charles R.	Boston	MA	02215	N/A
Vajda; Sandor	Medfield	MA	02050	N/A
Reznik; Gabriel O.	Boston	MA	02215	N/A
Smith; Cassandra L.	Boston	MA	02215	N/A
Pandori; Mark W.	San Diego	CA	92121	N/A

US-CL-CURRENT: 530/350; 530/402, 530/808, 530/810

ABSTRACT:

The present invention relates to streptavidin proteins and peptides having a altered physical properties such as an increased stability or increased or decreased affinity for binding biotin. The invention also relates to methods for the detection, identification, separation and isolation of targets using streptavidin proteins or peptides. Streptavidin with increased or reduced affinity allows for the use of the streptavidin-biotin coupling systems for detection and isolation systems wherein it is necessary to remove of one or the other of the binding partners. Such systems are useful for the purification of functional proteins and viable cells. The invention also relates to nucleic acids which encode these streptavidin proteins and peptides and to recombinant cells such as bacteria, yeast and mammalian cells which contain these nucleic acids.

31 Claims, 27 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 28

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KWIC	Image
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	-------

☐ 2. Document ID: US 6020145 A

Entry 2 of 36

File: USPT

Feb 1, 2000

TITLE: Methods for determining the presence of carcinoma using the antigen binding region of monoclonal antibody BR96

DATE-ISSUED: February 1, 2000

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Hellstrom; Ingegerd	Seattle	WA	N/A	N/A
Hellstrom; Karl Erik	Seattle	WA	N/A	N/A
Bruce; Kim Folger	Seattle	WA	N/A	N/A
Schreiber; George J.	Seattle	WA	N/A	N/A

US-CL-CURRENT: 435/7.23; 424/1.49, 424/131.1, 424/9.6, 435/7.1, 435/7.92, 435/7.95, 530/387.2, 530/388.1

ABSTRACT:

The present invention relates to novel antibodies, antibody fragments and antibody conjugates and single-chain immunotoxins reactive with human carcinoma cells. More particularly, the antibodies, conjugates and single-chain immunotoxins of the invention include: a murine monoclonal antibody, BR96; a human/murine chimeric antibody, ChiBR96; a F(ab')₂ fragment of BR96; ChiBR96-PE, ChiBR96-LysPE40, ChiBR96 F(ab')₂-LysPE40 and ChiBR96 Fab'-LysPE40 conjugates and recombinant BR96 sFv-PE40 immunotoxin. These molecules are reactive with a cell membrane antigen on the surface of human carcinomas. The BR96 antibody and its functional equivalents, displays a high degree of selectivity for carcinoma cells and possess the ability to mediate antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity activity. In addition, the antibodies of the invention internalize within the carcinoma cells to which they bind and are therefore particularly useful for therapeutic applications, for example, as the antibody component of antibody-drug or antibody toxin conjugates. The antibodies also have a unique feature in that they are cytotoxic when used in the unmodified form, at specified concentrations.

4 Claims, 76 Drawing figures

Exemplary Claim Number: 1,3

Number of Drawing Sheets: 74

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KWIC	Image
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	-------

3. Document ID. US 6015694 A

Entry 3 of 36

File: USPT

Jan 18, 2000

US-PAT-NO: 6015694
DOCUMENT-IDENTIFIER: US 6015694 A

TITLE: Method for stimulating an immune response utilizing recombinant alphavirus particles

DATE-ISSUED: January 18, 2000

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Dubensky, Jr.; Thomas W.	Rancho Sante Fe	CA	N/A	N/A
Polo; John M.	San Diego	CA	N/A	N/A
Chang; Steven M.W.	San Diego	CA	N/A	N/A
Jolly; Douglas J.	Leucadia	CA	N/A	N/A

US-CL-CURRENT: 435/69.3; 424/199.1, 424/204.1, 424/228.1, 424/234.1, 424/265.1, 424/274.1, 424/277.1, 536/23.5, 536/23.7, 536/23.72

ABSTRACT:

The present invention provides compositions and methods for utilizing recombinant alphavirus vectors. Also disclosed are compositions and methods for making and utilizing eukaryotic layered vector initiation systems.
11 Claims, 35 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 30

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KWIC	Image
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	-------

4. Document ID: US 6015686 A

Entry 4 of 36

File: USPT

Jan 18, 2000

US-PAT-NO: 6015686

DOCUMENT-IDENTIFIER: US 6015686 A

TITLE: Eukaryotic layered vector initiation systems

DATE-ISSUED: January 18, 2000

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Dubensky, Jr.; Thomas W.	Rancho Sante Fe	CA	N/A	N/A
Polo; John M.	San Diego	CA	N/A	N/A
Jolly; Douglas J.	Leucadia	CA	N/A	N/A
Driver; David A.	San Diego	CA	N/A	N/A

US-CL-CURRENT: 435/69.1; 435/320.1, 435/325, 435/410, 536/23.5, 536/23.72, 536/24.1

ABSTRACT:

The present invention provides compositions and methods for utilizing recombinant alphavirus vectors. Also disclosed are compositions and methods for making and utilizing eukaryotic layered vector initiation systems.
20 Claims, 37 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 30

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KWIC	Image
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	-------

5. Document ID: US 5985620 A

Entry 5 of 36

File: USPT

Nov 16, 1999

US-PAT-NO: 5985620
DOCUMENT-IDENTIFIER: US 5985620 A

TITLE: TNF-.alpha. Ribozymes

DATE-ISSUED: November 16, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Sioud; Mouldy	Oslo	N/A	N/A	NOX

US-CL-CURRENT: 435/91.31; 435/243, 435/320.1, 435/325, 435/440, 435/455, 435/471, 435/6, 435/91.1, 435/91.3, 435/91.33, 514/44, 536/23.1, 536/23.2, 536/24.5

ABSTRACT:

This invention describes compounds active against TNF-.alpha. mRNA. It further describes RNA molecules capable of conferring stability to RNA in vivo through an endogenous ribozyme binding protein(s). Possible mRNA molecules to be stabilized include ribozymes, antisense molecules and mRNA encoding polypeptides useful for protein production. The ribozymes and antisense molecules described herein are useful in mammals and plants, particularly suited for viral diseases. Methods of production and methods of use are also described.

24 Claims, 47 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 30

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KWIC	Image
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	-------

6. Document ID: US 5980896 A

Entry 6 of 36

File: USPT

Nov 9, 1999

US-PAT-NO: 5980896

DOCUMENT-IDENTIFIER: US 5980896 A

TITLE: Antibodies reactive with human carcinomas

DATE-ISSUED: November 9, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Hellstrom; Ingegerd	Seattle	WA	N/A	N/A
Hellstrom; Karl Erik	Seattle	WA	N/A	N/A
Bruce; Kim Folger	Seattle	WA	N/A	N/A
Schreiber; George J.	Redmond	WA	N/A	N/A
Siegall; Clay	Edmonds	WA	N/A	N/A
McAndrew; Stephen	Newtown	PA	N/A	N/A

US-CL-CURRENT: 424/182.1; 424/134.1, 424/135.1, 424/136.1, 424/138.1, 424/141.1, 424/155.1, 424/178.1, 424/181.1, 530/387.3, 530/387.5, 530/387.7, 530/391.7

ABSTRACT:

The present invention relates to novel antibodies, antibody fragments and antibody conjugates and single-chain immunotoxins reactive with human carcinoma cells. More particularly, the antibodies, conjugates and single-chain immunotoxins of the invention include: a murine monoclonal antibody, BR96; a human/murine chimeric antibody, ChiBR96; a F(ab')₂ fragment of BR96; ChiBR96-PE, ChiBR96-LysPE40, ChiBR96 F(ab')₂-LysPE40 and ChiBR96 Fab'-LysPE40 conjugates and recombinant BR96 sFv-PE40 immunotoxin. These molecules are reactive with a cell membrane antigen on the surface of human carcinomas. The BR96 antibody and its functional equivalents, displays a high degree of selectivity for carcinoma cells and possess the ability to mediate antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity activity. In addition, the antibodies of the invention internalize within the carcinoma cells to which they bind and are therefore particularly useful for therapeutic applications, for example, as the antibody component of antibody-drug or antibody-toxin conjugates. The antibodies also have a unique feature in that they are cytotoxic when used in the unmodified form, at specified concentrations.

35 Claims, 76 Drawing figures

35 Claims, 76 Drawing figures
Exemplary Claim Number: 16,34
Number of Drawing Sheets: 74

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KWIC	Image
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	-------

☒ 7. Document ID: US 5939265 A

Entry 7 of 36

File: USPT

Aug 17, 1999

US-PAT-NO: 5939265

DOCUMENT-IDENTIFIER: US 5939265 A

TITLE: Reagents and methods useful for detecting diseases of the lung

DATE-ISSUED: August 17, 1999

INVENTOR- INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Cohen; Maurice	Highland Park	IL	N/A	N/A
Friedman; Paula N.	Deerfield	IL	N/A	N/A
Gordon; Julian	Lake Bluff	IL	N/A	N/A
Hodges; Steven C.	Buffalo Grove	IL	N/A	N/A
Klass; Michael R.	Libertyville	IL	N/A	N/A
Kratochvil; Jon D.	Kenosha	WI	N/A	N/A
Roberts-Rapp; Lisa	Gurnee	IL	N/A	N/A
Russell; John C.	Kenosha	WI	N/A	N/A
Stroupe; Steven D.	Libertyville	IL	N/A	N/A

US-CL-CURRENT: 435/6; 435/320.1, 435/325, 536/23.1, 536/23.5

ABSTRACT:

A set of contiguous and partially overlapping RNA sequences and polypeptides encoded thereby, designated as LU103 and transcribed from lung tissue is described. A fully sequenced clone representing the longest continuous sequence of LU103 is also disclosed. These sequences are useful for detecting, diagnosing, staging, monitoring, prognosticating, preventing or treating, or determining the predisposition of an individual to diseases and conditions of the lung such as lung cancer.

21 Claims, 6 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 6

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KWIC	Image
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	-------

☐ 8. Document ID: US 5919702 A

Entry 8 of 36

File: USPT

Jul 6, 1999

US-PAT-NO: 5919702
DOCUMENT-IDENTIFIER: US 5919702 A

TITLE: Production of cartilage tissue using cells isolated from Wharton's jelly

DATE-ISSUED: July 6, 1999

INVENTOR INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Purchio; Anthony F.	La Jolla	CA	N/A	N/A
Naughton; Brian A.	El Cajon	CA	N/A	N/A
San Roman; Julia	San Diego	CA	N/A	N/A

US-CL-CURRENT: 435/378; 424/93.1, 435/325, 435/366, 435/377

ABSTRACT:

The invention relates to the isolation and use of pre-chondrocytes from the umbilical cord, specifically from Wharton's jelly, that give rise to chondrocytes which produce cartilage. The isolated pre-chondrocytes, or the chondrocytes to which they give rise, can be mitotically expanded in culture and used in the production of new cartilage tissue for therapeutic use. "Banks" of pre-chondrocytes or chondrocytes can be stored frozen, and thawed and used to produce new cartilage tissue as needed.

6 Claims, 15 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 11

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KMC	Image
------	-------	----------	-------	--------	----------------	------	-----------	--------	-----	-------

9. Document ID: US 5882864 A

Entry 9 of 36

File: USPT

Mar 16, 1999

US-PAT-NO: 5882864

DOCUMENT-IDENTIFIER: US 5882864 A

TITLE: Biomarkers and targets for diagnosis, prognosis and management of prostate disease

DATE-ISSUED: March 16, 1999

INVENTOR INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
An; Gang	Oklahoma City	OK	N/A	N/A
O'Hara; S. Mark	Oklahoma City	OK	N/A	N/A
Ralph; David	Edmond	OK	N/A	N/A
Veltri; Robert	Oklahoma City	OK	N/A	N/A

US-CL-CURRENT: 435/6; 435/91.2, 435/91.5, 435/91.51, 536/23.5, 536/24.31, 536/24.33

ABSTRACT:

Disclosed are diagnostic techniques for the detection of human prostate cancer. Genetic probes and methods useful in monitoring the progression and diagnosis of prostate cancer are described. The invention relates particularly to probes and methods for evaluating the presence of RNA species that are differentially expressed in prostate cancer compared to normal human prostate or benign prostatic hyperplasia.

64 Claims, 16 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 15

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KMC	Image
------	-------	----------	-------	--------	----------------	------	-----------	--------	-----	-------

10. Document ID: US 5879898 A

Entry 10 of 36

File: USPT

Mar 9, 1999

US-PAT-NO: 5879898
DOCUMENT-IDENTIFIER: US 9898 A

TITLE: Antibodies specific for peptide corresponding to CD44 exon 6, and use of these antibodies for diagnosis of tumors

DATE-ISSUED: March 9, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Tarin; David	Oxford	N/A	N/A	GBX
Matsumura; Yasuhiro	Tokyo	N/A	N/A	JPX

US-CL-CURRENT: 435/7.21; 435/430, 435/7.23, 435/70.21, 530/387.3, 530/387.7, 530/387.9, 530/388.2, 530/388.8, 530/388.85, 530/389.7

ABSTRACT:

There is marked over-expression of multiple spliced variants of the CD44 gene in tumor compared to counterpart normal tissue. This observation forms the basis of a method of diagnosing neoplasia by analysis of a sample of body tissue or body fluid or waste product. A new exon 6 of 129 bp has been located and sequenced. Antibodies specific to the exon have been prepared and are claimed as new compounds suitable for use in the detection of CD44 proteins and for the in vivo imaging and therapy of tumors.

13 Claims, 15 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 7

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KMC	Image
------	-------	----------	-------	--------	----------------	------	-----------	--------	-----	-------

☐ 11. Document ID: US 5876923 A

Entry 11 of 36

File: USPT

Mar 2, 1999

US-PAT-NO: 5876923

DOCUMENT-IDENTIFIER: US 5876923 A

TITLE: Herpes simplex virus ICP4 as an inhibitor of apoptosis

DATE-ISSUED: March 2, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Leopardi; Rosario	Chicago	IL	N/A	N/A
Roizman; Bernard	Chicago	IL	N/A	N/A

US-CL-CURRENT: 435/5; 424/93.1, 424/53.2, 435/6, 435/69.2, 514/44

ABSTRACT:

The ICP4 protein of herpes simplex virus plays an important role in the transactivation of viral genes. The present invention discloses that ICP4 also has the ability to inhibit apoptosis. This function appears to reside in functional domain distinct from the transactivating function, as indicated by studies using temperature sensitive mutants of ICP4 that transactivating function at elevated temperatures. Also disclosed are methods for inhibition of apoptosis using ICP4 or an ICP4 encoding gene, such as an alpha.4 gene, methods of inhibiting ICP4's apoptosis-inhibiting function, and methods for the production of recombinant proteins and treatment of HSV infections.

8 Claims, 13 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 13

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KMC	Image
------	-------	----------	-------	--------	----------------	------	-----------	--------	-----	-------

☐ 12. Document ID: US 5869045 A

Entry 12 of 36

File: USPT

Feb 9, 1999

US-PAT-NO: 5869045
DOCUMENT IDENTIFIER: US 5869045 A

TITLE: Antibody conjugates reactive with human carcinomas

DATE-ISSUED: February 9, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Hellstrom; Ingegerg	Seattle	WA	N/A	N/A
Hellstrom; Karl Erik	Seattle	WA	N/A	N/A
Bruce; Kim Folger	Seattle	WA	N/A	N/A
Schreiber; George J.	Seattle	WA	N/A	N/A

US-CL-CURRENT: 424/130.1; 424/134.1, 424/155.1, 530/387.7, 530/388.8, 530/391.1

ABSTRACT:

The present invention relates to novel antibodies, antibody fragments and antibody conjugates and single-chain immunotoxins reactive with human carcinoma cells. More particularly, the antibodies, conjugates and single-chain immunotoxins of the invention include: a murine monoclonal antibody, BR96; a human/murine chimeric antibody, ChiBR96; a F(ab')₂ fragment of BR96; ChiBR96-PE, ChiBR96-LysPE40, ChiBR96 F(ab')₂-LysPE40 and ChiBR96 Fab'-LysPE40 conjugates and recombinant BR96 sFv-PE40 immunotoxin. These molecules are reactive with a cell membrane antigen on the surface of human carcinomas. The BR96 antibody and its functional equivalents, displays a high degree of selectivity for carcinoma cells and possess the ability to mediate antibody dependent cellular cytotoxicity and complement-dependent cytotoxicity activity. In addition, the antibodies of the invention internalize within the carcinoma cells to which they bind and are therefore particularly useful for therapeutic applications, for example, as the antibody component of antibody-drug or antibody-toxin conjugates. The antibodies also have a unique feature in that they are cytotoxic when used in the unmodified form, at specified concentrations.

7 Claims, 75 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 74

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KWC	Image
------	-------	----------	-------	--------	----------------	------	-----------	--------	-----	-------

13. Document ID: US 5864028 A

Entry 13 of 36

File: USPT

Jan 26, 1999

US-PAT-NO: 5864028

DOCUMENT-IDENTIFIER: US 5864028 A

TITLE: Degradation resistant mRNA derivatives linked to TNF- α ribozymes

DATE-ISSUED: January 26, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Sioud; Mouldy	Oslo	N/A	N/A	NOX

US-CL-CURRENT: 536/23.1; 435/6, 435/91.31, 536/24.1, 536/24.5

ABSTRACT:

This invention describes compounds active against TNF- α mRNA. It further describes RNA molecules capable of conferring stability to RNA in vivo through an endogenous ribozyme binding protein(s). Possible mRNA molecules to be stabilized include ribozymes, antisense molecules and mRNA encoding polypeptides useful for protein production. The ribozymes and antisense molecules described herein are useful in mammals and plants, particularly suited for viral diseases. Methods of production and methods of use are also described.

5 Claims, 79 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 81

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KWIC	Image
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	-------

14. Document ID: US 5849580 A

Entry 14 of 36

File: USPT

Dec 15, 1998

US-PAT-NO: 5849580

DOCUMENT IDENTIFIER: US 5849580 A

TITLE: Nucleic acid encoding a NF-.kappa.B activation regulatory protein.
I.kappa.B.beta.

DATE-ISSUED: December 15, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Ghosh; Sankar	Madison	CT	N/A	N/A

US-CL-CURRENT: 435/325; 435/243, 435/320.1, 536/23.5

ABSTRACT:

The present invention provides a novel polypeptide, I.kappa.B-.beta., which binds to and affects NF-.kappa.B gene activation. Also provided is the nucleotide sequence encoding I.kappa.B-.beta. and methods of identifying compositions which affect I.kappa.B-.beta./NF-.kappa.B complexes. Methods of treatment of disorders associated with NF-.kappa.B induced gene activation are also described herein.

9 Claims, 20 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 18

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KWIC	Image
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	-------

15. Document ID: US 5843723 A

Entry 15 of 36

File: USPT

Dec 1, 1998

US-PAT-NO: 5843723

DOCUMENT-IDENTIFIER: US 5843723 A

TITLE: Alphavirus vector constructs

DATE-ISSUED: December 1, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Dubensky, Jr.; Thomas W.	Rancho Sante Fe	CA	N/A	N/A
Polo; John M.	San Diego	CA	N/A	N/A
Ibanez; Carlos E.	San Diego	CA	N/A	N/A
Chang; Stephen M. W.	San Diego	CA	N/A	N/A
Jolly; Douglas J.	Leucadia	CA	N/A	N/A
Driver; David A.	San Diego	CA	N/A	N/A
Belli; Barbara A.	San Diego	CA	N/A	N/A

US-CL-CURRENT: 435/69.3; 435/235.1, 435/320.1, 435/325

ABSTRACT:

The present invention provides compositions and method,, for utilizing recombinant alphavirus vectors.

47 Claims, 37 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 30

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KWIC	Image
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	-------

16. Document ID: US 5840297 A

US-PAT-NO: 5840297

DOCUMENT-IDENTIFIER: US 5840297 A

TITLE: Vaccine comprising anti-idiotypic antibody to chlamydia GLXA and process

DATE-ISSUED: November 24, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
MacDonald; Alex Bruce	Amherst	MA	N/A	N/A
An; Ling-Ling	La Jolla	CA	N/A	N/A
Sutton-Stuart; Elizabeth	Amherst	MA	N/A	N/A
Whittum-Hudson; Judith A.	Elkton	MD	N/A	N/A

US-CL-CURRENT: 424/131.1; 424/134.1, 424/150.1, 424/151.1, 424/263.1, 435/327, 435/340, 435/342, 530/387.2, 530/388.4, 530/388.6

ABSTRACT:

A genus specific chlamydia vaccine is provided which comprises an anti-idiotypic antibody capable of producing in an animal an anti-anti-idiotypic antibody which recognizes a glycoplipid exoantigen (GLXA) of chlamydia. The vaccine is produced by producing an idiotype antibody to GLXA which, in turn, is utilized to produce the anti-idiotypic antibody comprising the vaccine.

17 Claims, 17 Drawing figures

Exemplary Claim Number: 5

Number of Drawing Sheets: 9

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KWIC	Image
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	-------

☐ 17. Document ID: US 5821337 A

Entry 17 of 36

File: USPT

Oct 13, 1998

US-PAT-NO: 5821337

DOCUMENT-IDENTIFIER: US 5821337 A

TITLE: Immunoglobulin variants

DATE-ISSUED: October 13, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Carter; Paul J.	San Francisco	CA	N/A	N/A
Presta; Leonard G.	San Francisco	CA	N/A	N/A

US-CL-CURRENT: 530/387.3; 424/133.1, 530/350, 530/388.2

ABSTRACT:

Variant immunoglobulins, particularly humanized antibody polypeptides are provided, along with methods for their preparation and use. Consensus immunoglobulin sequences and structural models are also provided.

15 Claims, 12 Drawing figures

Exemplary Claim Number: 3

Number of Drawing Sheets: 12

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KWIC	Image
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	-------

☐ 18. Document ID: US 5814482 A

Entry 18 of 36

File: USPT

Sep 29, 1998

US-PAT-NO: 5814482
DOCUMENT-IDENTIFIER: US 5814482 A

TITLE: Eukaryotic layered vector initiation systems

DATE-ISSUED: September 29, 1998

INVENTOR- INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Dubensky, Jr.; Thomas W.	Rancho Sante Fe	CA	92067	N/A
Polo; John M.	San Diego	CA	92109	N/A
Jolly; Douglas J.	Leucadia	CA	92024	N/A
Driver; David A.	San Diego	CA	92117	N/A

US-CL-CURRENT: 435/69.3; 435/320.1, 536/23.1, 536/24.1

ABSTRACT:

The present invention provides compositions and methods for utilizing recombinant alphavirus vectors. Also disclosed are compositions and methods for making and utilizing eukaryotic layered vector initiation systems.
25 Claims, 37 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 30

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KMC	Image
------	-------	----------	-------	--------	----------------	------	-----------	--------	-----	-------

19. Document ID: US 5789245 A

Entry 19 of 36

File: USPT

Aug 4, 1998

US-PAT-NO: 5789245

DOCUMENT-IDENTIFIER: US 5789245 A

TITLE: Alphavirus structural protein expression cassettes

DATE-ISSUED: August 4, 1998

INVENTOR- INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Dubensky, Jr.; Thomas W.	Rancho Sante Fe	CA	N/A	N/A
Polo; John M.	San Diego	CA	N/A	N/A
Ibanez; Carlos E.	San Diego	CA	N/A	N/A
Chang; Stephen M. W.	San Diego	CA	N/A	N/A
Jolly; Douglas J.	Leucadia	CA	N/A	N/A
Driver; David A.	San Diego	CA	N/A	N/A

US-CL-CURRENT: 435/320.1; 435/325, 435/69.1, 536/23.72

ABSTRACT:

The present invention provides compositions and methods for utilizing recombinant alphavirus vectors. Also disclosed are compositions and methods for making and utilizing eukaryotic layered vector initiation systems.
29 Claims, 35 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 30

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KMC	Image
------	-------	----------	-------	--------	----------------	------	-----------	--------	-----	-------

20. Document ID: US 5760102 A

Entry 20 of 36

File: USPT

Jun 2, 1998

TITLE: Uses of denture adhesive containing aloe extract

DATE-ISSUED: June 1, 1993

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Hall; John E.	Grand Prairie	TX	N/A	N/A
Yates; Kenneth M.	Grand Prairie	TX	N/A	N/A

US-CL-CURRENT: 523/120; 433/180, 524/27, 524/78, 536/123.1, 536/4.1

ABSTRACT:

A method of adhering a denture, having a biocontact surface, to a gum or a roof of a mouth, containing the steps of: (1) Treating the biocontact surface of the denture with a denture adhesive composition containing a chemical substance derived from an aloe leaf to obtain a treated denture; and (2) placing the treated denture in close proximity to a gum or the roof of the mouth thereby engaging the treated denture with the gum or the roof of the mouth. A method of preparing a denture adhesive composition containing a chemical substance derived from an aloe leaf.

33 Claims, 22 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 11

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KWIC	Image
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	-------

Generate Collection

Term	Documents
MEDIUM.USPT.	434584
MEDIUMS.USPT.	12523
MEDIA.USPT.	156490
MEDIAS.USPT.	583
MEDIA.USPT.	156490
MEDIUM.USPT.	434584
MEDIUMS.USPT.	12523
MEDIAS.USPT.	583
(5 AND (MEDIUM OR MEDIA)) USPT.	36

Display 20 Documents

including document number

21

Display Format: REV

Change Format

Main Menu

Search Form

Posting Counts

Show S Numbers

Edit S Numbers

Help

Logout

Help

Logout

Main Menu

Search Form

Posting Counts

Show S Numbers

Edit S Numbers

Generate Collection

Search Results - Record(s) 21 through 36 of 36 returned.

☐ 21. Document ID: US 5744139 A

Entry 21 of 36

File: USPT

Apr 28, 1998

US-PAT-NO: 5744139

DOCUMENT-IDENTIFIER: US 5744139 A

TITLE: Insulin-like growth factor I (IGF-1) induced improvement of depressed T4/T8 ratios

DATE-ISSUED: April 28, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Kudsk, Kenneth A.	Memphis	TN	N/A	N/A

US-CL-CURRENT: 424/198.1; 424/185.1, 514/12, 514/2, 514/21, 530/300, 530/350, 530/399, 530/868

ABSTRACT:

A method for increasing the T4/T8 ratio in a human with a depressed T4/T8 ratio comprising administering insulin-like growth factor I (IGF-1) is disclosed.
 12 Claims, 63 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 27

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	RWD	Image
------	-------	----------	-------	--------	----------------	------	-----------	--------	-----	-------

☐ 22. Document ID: US 5741648 A

Entry 22 of 36

File: USPT

Apr 21, 1998

US-PAT-NO: 5741648
DOCUMENT IDENTIFIER: US 5741648 A

TITLE: Cell analysis method using quantitative fluorescence image analysis

DATE-ISSUED: April 21, 1998

INVENTOR INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Hemstreet, III; George P.	Oklahoma City	OK	N/A	N/A
Hurst; Robert E.	Oklahoma City	OK	N/A	N/A
Bonner; Rebecca B.	Oklahoma City	OK	N/A	N/A
Rao; Jian Yu	Edmond	OK	N/A	N/A

US-CL-CURRENT: 435/6; 435/7.21, 435/7.23, 436/63, 436/64, 436/813

ABSTRACT:

A system for evaluating one or more biochemical markers for evaluating individual cancer risk, cancer diagnosis and for monitoring therapeutic effectiveness and cancer recurrence, particularly of bladder cancer. The system uses automated quantitative fluorescence image analysis of a cell sample collected from a body organ. Cells are treated with a fixative solution which inhibits crystal formation. Cell images are selected and stored as grey level images for further analysis. Cell images may be corrected for autofluorescence using a novel autofluorescence correction method. A neural net computer may be used to distinguish true-positive images from false-positive images to improve accuracy of cancer risk assessment. Cells having images positive for a marker may be compared to threshold quantities related to predetermined cancer risk.

39 Claims, 31 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 24

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	RMC	Image
------	-------	----------	-------	--------	----------------	------	-----------	--------	-----	-------

☐ 23. Document ID: US 5733721 A

Entry 23 of 36

File: USPT

Mar 31, 1998

US-PAT-NO: 5723721
DOCUMENT IDENTIFIER: US 33/21 A

TITLE: Cell analysis method using quantitative fluorescence image analysis

DATE-ISSUED: March 31, 1998

INVENTOR- INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Hemstreet, III; George P.	Oklahoma City	OK	N/A	N/A
Hurst; Robert E.	Oklahoma City	OK	N/A	N/A
Bonner; Rebecca B.	Oklahoma City	OK	N/A	N/A
Rao; Jian Yu	Edmond	OK	N/A	N/A

US-CL-CURRENT: 435/6; 382/133, 435/7.23, 435/968, 435/973, 436/800, 436/805

ABSTRACT:

A system for evaluating one or more biochemical markers for evaluating individual cancer risk, cancer diagnosis and for monitoring therapeutic effectiveness and cancer recurrence, particularly of bladder cancer. The system uses automated quantitative fluorescence image analysis of a cell sample collected from a body organ. Cells are treated with a fixative solution which inhibits crystal formation. Cell images are selected and stored as grey level images for further analysis. Cell images may be corrected for autofluorescence using a novel autofluorescence correction method. A neural net computer may be used to distinguish true-positive images from false-positive images to improve accuracy of cancer risk assessment. Cells having images positive for a marker may be compared to threshold quantities related to predetermined cancer risk.

143 Claims, 31 Drawing figures

Exemplary Claim Number: 143

Number of Drawing Sheets: 24

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KWC	Image
------	-------	----------	-------	--------	----------------	------	-----------	--------	-----	-------

☐ 24. Document ID: US 5716793 A

Entry 24 of 36

File: USPT

Feb 10, 1998

US-PAT-NO: 5716793

DOCUMENT-IDENTIFIER: US 5716793 A

TITLE: Method for diagnosing a patient for chlamydia

DATE-ISSUED: February 10, 1998

INVENTOR- INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
MacDonald; Alex Bruce	Amherst	MA	N/A	N/A
Stuart; Elizabeth S.	Amherst	MA	N/A	N/A
An; Ling Ling	La Jolla	CA	N/A	N/A
Whipkey; Myron D.	Portland	ME	N/A	N/A

US-CL-CURRENT: 435/7.36; 424/150.1, 424/163.1, 424/263.1, 435/7.32, 435/7.9, 435/7.92, 435/7.94, 435/7.95, 435/965, 436/518, 436/536, 436/548, 436/811, 530/388.4, 530/382.5

ABSTRACT:

A method of detecting chlamydia in a extracellular sample is provided which comprises contacting the sample with an idiotype antibody to GLXA to form an immunocomplex and detecting the immunocomplex.

10 Claims, 17 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 9

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KWC	Image
------	-------	----------	-------	--------	----------------	------	-----------	--------	-----	-------

25. Document ID: US 5688657 A

Entry 25 of 26

File: USPT

Nov 18, 1997

US-PAT-NO: 5688657

DOCUMENT-IDENTIFIER: US 5688657 A

TITLE: Monoclonal antibodies against human colon carcinoma-associated antigens and uses therefor

DATE-ISSUED: November 18, 1997

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Tsang; Kwong Y.	Bethesda	MD	N/A	N/A
Arlon; Myron	Great Neck	NY	N/A	N/A

US-CL-CURRENT: 435/7.23, 435/325, 435/328, 435/329, 435/330, 435/332, 435/344, 435/40.51, 435/40.52, 435/7.1, 435/7.2, 530/387.1, 530/387.3, 530/387.5, 530/387.7, 530/388.1, 530/388.8, 530/391.1, 530/391.3, 530/391.7

ABSTRACT:

Monoclonal antibodies, in particular 33.28 and 31.1, and chimeric antibodies, in particular mouse/human chimeric Chi #1 specific for glycoprotein antigens of colon carcinoma-associated antigens which are immunogenic in humans, are disclosed. Such antibodies, and fragments and derivatives thereof, are useful in immunodiagnosis and immunotherapy of human colon, breast, and ovarian cancer, and for purification of antigens which can serve as immunotherapeutic agents. Methods of detecting the colon carcinoma-associated antigen in a sample, and methods for treating subjects having colon, breast, and ovarian carcinomas are disclosed.

50 Claims, 4 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 4

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KMC	Image
------	-------	----------	-------	--------	----------------	------	-----------	--------	-----	-------

26. Document ID: US 5665540 A

Entry 26 of 36

File: USPT

Sep 9, 1997

US-PAT-NO: 5665540

DOCUMENT-IDENTIFIER: US 5665540 A

TITLE: Multicolor in situ hybridization methods for genetic testing

DATE-ISSUED: September 9, 1997

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Lebo; Roger V.	San Francisco	CA	N/A	N/A

US-CL-CURRENT: 435/6; 436/811

ABSTRACT:

This invention relates to novel methods of optimally analyzing commonly obtained prenatal cell samples by in situ hybridization. In addition, this method diagnoses gene deletion and gene multiplication using multicolor in situ hybridization. A method is also provided to use multicolor in situ hybridization to identify chromosomal haplotypes co-segregating with disease-related genetic alterations and with normal genes. This haplotype in situ protocol simplifies haplotype segregation analysis in pedigrees.

21 Claims, 9 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 2

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KMC	Image
------	-------	----------	-------	--------	----------------	------	-----------	--------	-----	-------

27. Document ID: US 5656271 A

US-PAT-NO: 5656271

DOCUMENT-IDENTIFIER: US 5656271 A

TITLE: Oral vaccine comprising anti idiotypic antibody to chlamydia glycolipid
exoantigen and process

DATE ISSUED: August 12, 1997

INVENTOR INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
MacDonald; Alex Bruce	Hatfield	MA	N/A	N/A
Whittum-Hudson; Judith A.	Elkton	MD	N/A	N/A
Saltzman; William Mark	Baltimore	MD	N/A	N/A

US-CL-CURRENT: 424/131.1; 424/151.1, 424/263.1, 424/436, 424/492, 424/493, 424/497,
530/387.2, 530/388.4, 530/389.5

ABSTRACT:

A genus specific chlamydia oral or injectable vaccine is provided which comprises an anti-idiotypic antibody capable of producing in an animal an anti-idiotypic antibody or Fab fragment thereof enclosed in microspheres formed of a pharmacologically acceptable polymer is capable of producing in an animal an anti-anti-idiotypic immune response (serum antibody, secretory antibody or T-cell response) which recognizes a glycolipid exoantigen (GLXA) of chlamydia. The oral or injectable vaccine is produced from an idiotypic antibody to GLXA which, in turn, is utilized to produce the anti-idiotypic antibody.

15 Claims, 19 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 10

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KWC	Image
------	-------	----------	-------	--------	----------------	------	-----------	--------	-----	-------

28. Document ID: US 5654148 A

Entry 28 of 36

File: USPT

Aug 5, 1997

US-PAT-NO: 5654148

DOCUMENT-IDENTIFIER: US 5654148 A

TITLE: Multicolor in situ hybridization methods for genetic testing

DATE-ISSUED: August 5, 1997

INVENTOR INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Lebo; Roger V.	San Francisco	CA	N/A	N/A

US-CL-CURRENT: 435/6; 435/5

ABSTRACT:

This invention relates to novel methods of optimally analyzing commonly obtained prenatal cell samples by in situ hybridization. In addition, this method diagnoses gene deletion and gene multiplication using multicolor in situ hybridization. A method is also provided to use multicolor in situ hybridization to identify chromosomal haplotypes co-segregating with disease-related genetic alterations and with normal genes. This haplotype in situ protocol simplifies haplotype segregation analysis in pedigrees.

6 Claims, 9 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 2

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KWC	Image
------	-------	----------	-------	--------	----------------	------	-----------	--------	-----	-------

29. Document ID: US 5597898 A

Entry 29 of 36

File: USPT

Jan 28, 1997

US-PAT-NO: 5597898
DOCUMENT IDENTIFIER: US 5597898 A

TITLE: NF-.kappa.B activation regulatory protein, I.kappa.B .beta.

DATE ISSUED: January 28, 1997

INVENTOR INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Ghosh; Sankar	Madison	CT	N/A	N/A

US-CL-CURRENT: 530/350

ABSTRACT:

The present invention provides a novel polypeptide, I.kappa.B-.beta., which binds to and affects NF-.kappa.B gene activation. Also provided is the nucleotide sequence encoding I.kappa.B-.beta. and methods of identifying compositions which affect I.kappa.B-.beta.\.NF-.kappa.B complexes. Methods of treatment of disorders associated with NF-.kappa.B induced gene activation are also described herein.
1 Claims, 20 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 13

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KWC	Image
------	-------	----------	-------	--------	----------------	------	-----------	--------	-----	-------

30. Document ID: US 5447842 A

Entry 30 of 36

File: USPT

Sep 5, 1995

US-PAT-NO: 5447842

DOCUMENT-IDENTIFIER: US 5447842 A

TITLE: Fetal cell recovery method

DATE-ISSUED: September 5, 1995

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Simons; Malcolm J.	Glenluce	N/A	N/A	GBX

US-CL-CURRENT: 435/6; 435/2, 435/29, 435/30, 435/378, 435/7.21, 435/7.24, 435/7.25

ABSTRACT:

The present invention provides a method for selectively recovering fetal cells from a maternal blood sample. The method is performed on a blood sample from a pregnant woman having different first and second cell surface antigens expressed by a first allele of a polymorphic genetic locus and a second allele of a polymorphic genetic locus. The method separates maternal and fetal cells based on differential reactivities of the cells to antibodies specific for polymorphic cell surface antigens, particularly the HLA antigens. In particular, the fetal and maternal cells are separated based on the non-reactivity of the fetal cells to an antibody specific for a cell surface antigen encoded by a non transmitted maternal allele. The method can be performed using solid phase-affixed antibody and recovering non-bound cells or using fluorescent labeled antibody and recovering unlabeled cells by fluorescence-activated cell sorting. In a preferred embodiment, the cells are also contacted with a second antibody specific for the second cell surface antigen. Fetal cells are separated based on their reaction with, at most, one of the antibodies.
26 Claims, 0 Drawing figures
Exemplary Claim Number: 1

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KWC	Image
------	-------	----------	-------	--------	----------------	------	-----------	--------	-----	-------

31. Document ID: US 5292636 A

Entry 31 of 36

File: USPT

Mar 3, 1994

TITLE: Therapeutic and diagnostic methods using soluble T cell surface molecules

DATE-ISSUED: March 8, 1994

INVENTOR INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Kung; Patrick C.	Lexington	MA	N/A	N/A
Ip; Stephen H.	Sudbury	MA	N/A	N/A
Brown; Michael C.	Wayland	MA	N/A	N/A
MacKeen; Linda A.	Elkins Park	PA	N/A	N/A

US-CL-CURRENT: 435/5, 435/34, 435/7.23, 435/7.24, 435/7.9, 435/7.94, 435/974, 435/975, 436/506, 436/518, 436/536, 436/548, 436/811, 436/813

ABSTRACT:

The present invention is directed to the measurement of soluble T cell growth factor receptors, soluble T cell differentiation antigens, or related soluble molecules or fragments thereof, and the use of such measurements in the diagnosis, staging, and therapy of diseases and disorders. Specific embodiments involve the diagnosis and monitoring of therapy using absolute values of such soluble molecules. Further embodiments involve detecting a change in the levels of such soluble molecules, in the diagnosis and therapy of diseases and disorders. In specific embodiments, measurements of interleukin-2 receptor levels can be made to detect lung cancer, or to stage squamous cell lung carcinoma. In other embodiments, detection of increases in both soluble IL2R and creatinine in the body fluid of a transplant patient can be used to differentially diagnose renal allograft rejection from infection. The invention is also directed to methods for measurement of soluble CD4 antigens, which measurements can be used, in a specific embodiment, to diagnose a state of immune activation, to diagnose rheumatoid arthritis, to monitor therapeutic efficacy (e.g. of AIDS treatments), or to stage adult T cell leukemia in a patient. In another aspect, the invention relates to the detection, staging, and monitoring of therapy of diseases and disorders by measuring a plurality of soluble T cell markers.

37 Claims, 35 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 28

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KMC	Image
------	-------	----------	-------	--------	----------------	------	-----------	--------	-----	-------

☐ 32. Document ID: US 5242820 A

Entry 32 of 36

File: USPT

Sep 7, 1993

US-PAT-NO: 5242820
DOCUMENT-IDENTIFIER: US 5242820 A

TITLE: Pathogenic mycoplasma

DATE-ISSUED: September 7, 1991

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Lo; Shyh-Ching	Potomac	MD	N/A	N/A

US-CL-CURRENT: 435/252.1; 435/5. 435/872

ABSTRACT:

The invention relates to a novel pathogenic mycoplasma isolated from patients with Acquired Immune Deficiency Syndrome (AIDS) and its use in detecting antibodies in sera of AIDS patients, patients with AIDS-related complex (ARC) or patients dying of diseases and symptoms resembling AIDS diseases. The invention further relates to specific DNA sequences, antibodies against the pathogenic mycoplasma, and their use in detecting DNA or antigens of the pathogenic mycoplasma or other genetically and serologically closely related mycoplasmas in infected tissue of patients with AIDS or ARC or patients dying of symptoms resembling AIDS diseases. The invention still further relates to a variety of different forms of vaccine against mycoplasma infection in humans and/or animals.

3 Claims, 120 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 39

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KWIC	Image
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	-------

☐ 33. Document ID US 5225542 A

Entry 33 of 36

File: USPT

Jul 6, 1993

US-PAT-NO: 5225542

DOCUMENT-IDENTIFIER: US 5225542 A

TITLE: Specific carbohydrate-binding proteins (lectins) of mammalian tumor cells

DATE-ISSUED: July 6, 1993

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Cramer; Friedrich	Goettingen	N/A	N/A	DEX
Gabius; Hans-Joachim	Goettingen	N/A	N/A	DEX

US-CL-CURRENT: 530/336

ABSTRACT:

Carbohydrate-binding proteins (lectins) of mammalian tumor cells and processes for their preparation. These lectins, the corresponding carbohydrates and the corresponding monoclonal antibodies are suitable for rapid, reliable and precise differential diagnosis of tumors and for the product of pharmaceutical compositions for the treatment of tumors.

29 Claims, 2 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 2

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KWIC	Image
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	-------

☐ 34. Document ID: US 4917890 A

Entry 34 of 36

File: USPT

Apr 17, 1990

US-PAT-NO: 4917890
DOCUMENT IDENTIFIER: US 4917890 A

TITLE: Processes for preparation of aloe products, products produced thereby and compositions thereof

DATE-ISSUED: April 17, 1990

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
McAnalley; Bill H.	Grand Prairie	TX	N/A	N/A

US-CL-CURRENT: 424/195.1; 424/DIG.13, 426/658, 514/25, 514/458

ABSTRACT:

Processes for producing aloe extracts including the separation of the leaves of the aloe plant into distinct portions. In particular, a first process is described for producing an aloe extract which is substantially free of anthraquinone-rich yellow sap and a second process is described for extracting the active chemical substance in the aloe plant.

The active chemical substance in the aloe plant is extracted from aloe leaves and its characteristic properties are described.

63 Claims, 28 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 28

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KWIC	Image
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	-------

35. Document ID: US 4775620 A

Entry 35 of 36

File: USPT

Oct 4, 1988

US-PAT-NO: 4775620

DOCUMENT-IDENTIFIER: US 4775620 A

TITLE: Cytokeratin tumor markers and assays for their detection

DATE-ISSUED: October 4, 1988

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Cardiff; Robert D.	Davis	CA	N/A	N/A
Rossitto; Paul V.	Sacramento	CA	N/A	N/A
Brabon; Alan C.	Andrews Air Force Base	MD	N/A	N/A

US-CL-CURRENT: 435/7.23; 435/29, 435/70.21, 435/813, 435/975, 436/519, 436/548, 436/813, 530/357, 530/388.2, 530/388.85, 530/828

ABSTRACT:

Methods and compositions are provided for identifying patients suffering from neoplastic diseases such as breast cancer. It has been found that neoplastic epithelial cells, including neoplastic mammary epithelial cells, release a particular N-terminal blocked, soluble cytokeratin into circulation. The presence of this cytokeratin is diagnostic of neoplastic disease.

34 Claims, 0 Drawing figures

Exemplary Claim Number: 1

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KWIC	Image
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	-------

36. Document ID: US 4735935 A

Entry 36 of 36

File: USPT

Apr 5, 1988

US-PAT-NO: 4735935
DOCUMENT IDENTIFIER: US 4735935 A

TITLE: Process for preparation of aloe products products, produced thereby and compositions thereof

DATE ISSUED: April 5, 1988

INVENTOR INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
McAnalley; Bill H.	Grand Prairie	TX	N/A	N/A

US-CL-CURRENT: 514/53; 124/DIG.13, 514/54, 514/647, 535/123, 535/53

ABSTRACT:

Process for producing aloe extracts including the separation of the leaves of the aloe plant into distinct portions. In particular, a first process is described for producing an aloe extract which is substantially free of anthraquinone-rich yellow sap and a second process is described for extracting the active chemical substance in the aloe plant.

The active chemical substance in the aloe plant is extracted from aloe leaves and its characteristic properties are described.

5 Claims, 32 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 28

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KWIC	Image
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	-------

Generate Collection

Term	Documents
MEDIUM.USPT.	434584
MEDIUMS.USPT	12523
MEDIA.USPT.	156490
MEDIAS.USPT.	583
MEDIA.USPT.	156490
MEDIUM.USPT	434584
MEDIUMS.USPT.	12523
MEDIAS.USPT.	583
(5 AND (MEDIUM OR MEDIA)) USPT.	36

Display 20 Documents

including document number

36

Display Format:

FEV

Change Format

Main Menu

Search Form

Posting Counts

Show S Numbers

Edit S Numbers

Help

Logout